ReviewMacromolecular bioscience2026
Design of Nanocarriers for Kidney Targeted Delivery of Nucleic Acid Therapeutics.
Review in Macromolecular bioscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Driven by recent successful clinical translation, nucleic acid therapeutics are being actively investigated to expand their applications to various diseases, including renal genetic disorders. As life expectancy increases and the burden of renal diseases continues to rise, nucleic acid therapeutics are considered promising alternatives to conventional treatments. This review summarizes key considerations in the design and fabrication of nanocarriers for the systemic delivery of nucleic acid therapeutics to the kidneys. Key aspects of the renal microenvironment are discussed to guide the design of nanocarriers, including conjugates and nanoparticles. This review also covers renal genetic disorders and nucleic acid-based treatment approaches, including small interfering RNAs (siRNAs), clustered regularly interspaced short palindromic repeats (CRISPR) systems, and messenger RNA (mRNA) therapeutics. In particular, recent strategies for kidney-targeted nanocarriers are highlighted, with an emphasis on their efficacy, challenges, and limitations. Perspectives on the design of nanocarriers for systemic nucleic acid delivery to the kidneys are also provided, offering insights into potential therapeutic approaches for renal genetic disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.